Researchers want to see if the drug palifermin improves the results of allogeneic SCT from HLA-matched unrelated donors.
This trial is currently open and accepting patients.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Patients meeting below eligibility criteria are eligible to receive suitable disease specific therapy for the purposes of disease control while the donor search takes place
Research Phase Inclusion Criteria:
Verification of donor eligibility (clearance must be received from the NMDP)
Donors are evaluated by NMDP affiliated donor centers per NMDP Standards .
EXCLUSION CRITERIA (applies to all phases of this protocol) :
Phase 1/2
Enrollment: 50 patients (estimated)
View MoreView all clinical trial locations sorted by state.
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message